(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted ...
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's ...
Lilly’s capacity expansion is ramping up ahead of initial expectations, analysts say. (Maddie McGarvey for The Wall Street Journal) Supply constraints for a popular class of diabetes and obesity drugs ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...